Technical Papers
Mathematical Models
2009
Carpenter D, Grimmer J. The Trouble with Deadlines. 2009.
Carpenter D, Grimmer J. The Trouble with Deadlines. 2009.
2007
Carpenter D, Ting M. “Regulatory Errors with Endogenous Agendas”. American Journal of Political Science . 2007;51(4):835–853.
Carpenter D, Ting M. “Regulatory Errors with Endogenous Agendas”. American Journal of Political Science . 2007;51(4):835–853.
2004
Carpenter D. “Protection without Capture: Dynamic Product Approval by a Politically Responsive Learning Regulator”. American Political Science Review . 2004;98(4):613–631.
Carpenter D. “Protection without Capture: Dynamic Product Approval by a Politically Responsive Learning Regulator”. American Political Science Review . 2004;98(4):613–631.
Carpenter D, Ting M. A Theory of Approval Regulation. 2004.
Carpenter D, Ting M. A Theory of Approval Regulation. 2004.
2003
Carpenter D, Meier K, Krause G. Why Do Bureaucrats Delay? Lessons from a Stochastic Optimal Stopping Model of Product Approval” forthcoming. 2003.
Carpenter D, Meier K, Krause G. Why Do Bureaucrats Delay? Lessons from a Stochastic Optimal Stopping Model of Product Approval” forthcoming. 2003.
Empirical/Statistical Studies
2012
Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The Complications of Controlling Agency Time Discretion: FDA Deadlines and Postmarket Drug Safety. American Journal of Political Science. 2012.
Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The Complications of Controlling Agency Time Discretion: FDA Deadlines and Postmarket Drug Safety. American Journal of Political Science. 2012.
2010
Carpenter D, Moffitt S, Moore C, Rynbrandt R, Ting M, Yohai I, Zucker EJ. Early-Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review. Journal of Law Economics and Organization . 2010;26(2).
Carpenter D, Moffitt S, Moore C, Rynbrandt R, Ting M, Yohai I, Zucker EJ. Early-Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review. Journal of Law Economics and Organization . 2010;26(2).
2008
Carpenter D, Zucker EJ, Avorn J. Drug Review Deadlines and Subsequent Safety Problems. New England Journal of Medicine . 2008;358(13):1354–61.
Carpenter D, Zucker EJ, Avorn J. Drug Review Deadlines and Subsequent Safety Problems. New England Journal of Medicine . 2008;358(13):1354–61.
2007
Carpenter D, Bowers J, Grimmer J, Moffitt S, Nall C, Zucker EJ. Deadline Effects in Regulatory Review: A Methodological and Empirical Analysis. 2007.
Carpenter D, Bowers J, Grimmer J, Moffitt S, Nall C, Zucker EJ. Deadline Effects in Regulatory Review: A Methodological and Empirical Analysis. 2007.
2004
Carpenter D, Feinstein B, Moore C, Turenne M, Yohai I, Zucker EJ. Why Do Bigger Firms Receive Faster Drug Approvals? 2004.
Carpenter D, Feinstein B, Moore C, Turenne M, Yohai I, Zucker EJ. Why Do Bigger Firms Receive Faster Drug Approvals? 2004.
2002
Carpenter D. Groups the Media Agency Waiting Costs and FDA Drug Approval. American Journal of Political Science. 2002;46(2):490–505.
Carpenter D. Groups the Media Agency Waiting Costs and FDA Drug Approval. American Journal of Political Science. 2002;46(2):490–505.